QC
GPCR icon

Quadrature Capital’s Structure Therapeutics GPCR Stock Holding History

Quadrature Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,761
Closed -$888K – 1577
2025
Q4 		$888K Buy
+12,761
New +$521K 0.01% 550
2025
Q3 		– Sell
-16,079
Closed -$334K – 1211
2025
Q2 		$334K Buy
+16,079
New +$354K 0.01% 669

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Quadrature Capital's GPCR Position: Q1 2026 in Review

Quadrature Capital sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 12,761 shares — an estimated $888K sold.

Quadrature Capital first reported a position in GPCR in Q2 2025 and held it in 2 quarters. The position peaked at $888K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Quadrature Capital reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 12,761 Structure Therapeutics shares in Q1 2026, an estimated $888K.
  • Quadrature Capital first reported a position in Structure Therapeutics in Q2 2025 and held it in 2 quarters.
  • Quadrature Capital's Structure Therapeutics position peaked at $888K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.